Back to news

Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform

Globe Newswire•17/11/2026•08:30 ET
1

Key Highlights

  • ➤Conexeu (CNXU) begins early-stage development of W.A.F.E.R. Sheet and W.A.F.E.R. Lattice
  • ➤W.A.F.E.R. Sheet targets broad wound surfaces in a dry, flexible format
  • ➤W.A.F.E.R. Lattice targets large volumetric defects as a shapeable scaffold
  • ➤Flowable CXU™ 510(k) submission remains targeted for first calendar quarter of 2027
  • ➤W.A.F.E.R. formats have not entered preclinical studies and lack regulatory timing

Expert Statements

Miles Harrison, President and Chief Executive Officer of Conexeu Sciences

“Wound care is where CXU™ begins, and clinicians treat every kind of wound, from shallow surfaces to large, deep defects. With W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, we are beginning to explore how the CXU™ platform might be adapted to different wound geometries. Our near-term focus remains the planned 510(k) submission for our flowable device candidate in the first calendar quarter of 2027; the fabricated formats are early-stage and will follow their own development and regulatory path.”

Claudia Chavez-Munoz, Chief Scientific Officer of Conexeu Sciences

“Expanding our laboratory and research and development team has given us the capacity to study CXU™ beyond its flowable presentation. W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice are early-stage design concepts; our immediate work is to fabricate them reproducibly and characterize their structural and handling properties followed by preclinical evaluation.”

Highlights * Conexeu has begun development of W.A.F.E.R.™, a fabricated, collagen-based scaffold designed to provide structural support across broad wound surfaces and large volumetric defects. * W.A.F.E.R.™ Sheet is being designed as a flexible sheet for potential use in a dry (lyophilized) state at the point of care, and to conform to broad wound surfaces. * W.A.F.E.R.™ Lattice is being designed as a lyophilized, three-dimensional scaffold for large volumetric defects, with the intent of allowing clinicians to shape it with a scalpel at the point of care. * Designed to be trimmed and shaped with a scalpel at the point of care, the two new formats complement the Company’s flowable CXU™ device candidate and are intended for evaluation in large defects. * Conexeu continues to target its planned FDA 510(k) submission for its flowable lead wound-care device candidate in the first calendar quarter of 2027, subject to successful completion of required testing, manufacturing activities and regulatory documentation. RENO, Nev., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (link) (“Conexeu” or the “Company”), a preclinical-stage medical device company advancing CXU™, an investigational collagen-based scaffold platform, today announced the development of WIDE APPLICATION FABRICATED EXTRACELLULAR MATRIX FOR RESTORATION™ (W.A.F.E.R.™), two additional fabricated CXU™ formats for wound management: W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in